Completed PHASE2 INTERVENTIONAL 2-arm NCT04492514

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Sponsor: Kiniksa Pharmaceuticals, Ltd.

Conditions COVID 19 Pneumonia SARS-CoV 2

Updated 6 times since 2020 Last updated: Dec 3, 2024 Started: May 20, 2020 Primary completion: Nov 16, 2020 Completion: Nov 16, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04492514, this PHASE2 trial focuses on COVID 19 and Pneumonia and remains completed. Sponsored by Kiniksa Pharmaceuticals, Ltd., it has been updated 6 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Jan 2025 — Present [monthly]

Completed PHASE2

Status: Unknown → Completed
Sep 2024 — Jan 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Sep 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Sep 2022 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kiniksa Pharmaceuticals, Ltd.
Kristin Hudock

Data source: University of Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States